Company

Spring Discovery

Last updated 2026-05-30· 1 min read

Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.

What it does

Spring Discovery uses high-throughput cellular imaging combined with machine-learning models to characterise the "phenotypic signature" of aging at the cellular level, then screens libraries of compounds for those that reverse the signature.

The approach is phenotypic rather than target-based — the hypothesis is that aging is too complex to address one target at a time, so screening for whole-cell rejuvenation signatures finds drugs that conventional target-based discovery would miss.

Founders and funding

Founded 2018 by ex-Google engineers and Stanford-Greg Brockman alumni. Significant Series B funding in 2021. Quiet on public communications; remains in stealth on specific programmes.

Why it matters

Spring is one of several companies betting that AI + phenotypic screening reshapes how aging-modifying compounds are discovered. The broader bet aligns with Insilico Medicine, NewLimit, BioAge, and a growing cluster of AI-first longevity biotechs.

What they do

Spring Discovery is a computational-biology company applying machine learning to accelerate the identification of geroprotective interventions. Its platform enables high-throughput screening of compounds against multi-parametric aging phenotypes rather than single disease endpoints.

Approach

Phenotypic screening in aged model systems (mice, invertebrates, cells) with rich imaging and multi-omics readouts.
ML-based classification of aging phenotype signatures.
Iterative screening to identify compounds that generalise across multiple aging endpoints.

Position in the field

Spring Discovery represents the computational-first cohort of longevity biotechs, alongside Insilico Medicine and Insitro. The bet is that aging biology is too complex to be reduced to single-target drug discovery and requires phenotypic + computational approaches.